20 Hrs
Source:
مباشر
Afalon Pharma signs local Denosumab production deal
Avallon Pharma announced the signing of a strategic and exclusive agreement with Bio-Thera Solutions to localize and manufacture the drug "Dupilumab" in the Kingdom of Saudi Arabia and the Middle East and North Africa region. The aim is to enhance the portfolio of biological medicines and generate revenues of up to 400 million SAR within the first seven years after the expected launch in 2031. Dupilumab is a monoclonal antibody used to treat chronic inflammatory diseases such as asthma and atopic dermatitis. Bio-Thera will be responsible for the development and manufacturing of the product, while Avallon Pharma will handle obtaining regulatory approvals and marketing the product. There is also the potential to transfer manufacturing technology to its facilities in Saudi Arabia, representing a strategic step toward local industry development in line with Saudi Vision 2030.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)